These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 26549305

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
    Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI.
    Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H.
    Thromb Haemost; 2016 Sep 27; 116(4):747-53. PubMed ID: 27440518
    [Abstract] [Full Text] [Related]

  • 9. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
    Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR.
    Thromb Haemost; 2017 Dec 27; 117(12):2406-2414. PubMed ID: 29212128
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
    Amin A, Jing Y, Trocio J, Lin J, Lingohr-Smith M, Graham J.
    J Med Econ; 2014 Nov 27; 17(11):763-70. PubMed ID: 25078794
    [Abstract] [Full Text] [Related]

  • 11. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA, Snead JA, Cheng-Lai A.
    Cardiol Rev; 2016 Nov 27; 24(4):205-10. PubMed ID: 26991962
    [Abstract] [Full Text] [Related]

  • 12. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
    Blann AD, Boriani G, Lip GY.
    Europace; 2016 Oct 27; 18(10):1507-1513. PubMed ID: 27876695
    [Abstract] [Full Text] [Related]

  • 13. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
    Vanassche T, Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Chen CZ, Cohen AT, Grosso MA, Medina AP, Mercuri MF, Winters SM, Zhang G, Weitz JI, Raskob GE, Büller HR.
    Thromb Res; 2018 Feb 27; 162():7-14. PubMed ID: 29248859
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV, Ustyugova A, Urbich M, Lamotte M, Sunderland T.
    Thromb Haemost; 2015 Oct 27; 114(4):778-92. PubMed ID: 26272227
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG, Walker J, Brown KS, Zhang G, Lin M, Grosso MA, Mercuri MF.
    Heart; 2017 Nov 27; 103(22):1800-1805. PubMed ID: 28689179
    [Abstract] [Full Text] [Related]

  • 19. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P, Le HH, Raymond V, Mtibaa M, Moshyk A.
    J Med Econ; 2016 Jun 27; 19(6):557-67. PubMed ID: 26761644
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
    Vilain KA, Yang MC, Hui Tan EC, Wang K, Li H, Hsu WH, Giugliano RP, Cohen DJ, Magnuson EA, ENGAGE AF – TIMI 48 Investigators.
    Value Health Reg Issues; 2017 May 27; 12():74-83. PubMed ID: 28648320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.